EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Modulation of oxidation-related immune markers by lipid-lowering medications in individuals with elevated lipoprotein(a)

Amalia Despoina Koutsogianni, Fotios Barkas, Constantinos Tellis, Alexandros Tselepis, George Liamis, Sotirios Tsimikas, Evangelos Liberopoulos

Clinical Research in Cardiology · 2026-08 · 115 (8) · 1400-1409

DOI: 10.1007/s00392-026-02896-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Research in Cardiology, online erschienen am 23.03.2026. Verfasst von Amalia Despoina Koutsogianni und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece. Hauptthemen laut MEDLINE: Lipoprotein(a), Ezetimibe, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Autoantibodies. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hellenic Atherosclerosis Society, University of Athens.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Oxidative modification of apolipoprotein B-100 (apoB) containing particles and subsequent immune responses contribute to the pathogenesis of atherosclerosis. Circulating IgG and IgM apoB-containing immune complexes (apoB-IC) and autoantibodies to a malondialdehyde mimotope (anti-MDA-mimotope) serve as biomarkers of oxidative stress and immune activation in atherosclerotic cardiovascular disease. Elevated lipoprotein(a) [Lp(a)] is associated with increased oxidative burden and immune activation.

Purpose

To investigate the effect of lipid-lowering medications on IgG and IgM apoB-IC and IgG and IgM autoantibodies to an MDA-mimotope in individuals with elevated lipoprotein(a) [Lp(a)] concentrations.

Methods

In this prospective study, patients ( n = 70) with Lp(a) levels ≥ 75 nmol/L were assigned to 3 treatment regimens according to current guidelines: high-intensity statin monotherapy ( n = 28), ezetimibe added to high-intensity statin ( n = 31) and proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) added to high-intensity statin plus ezetimibe ( n = 11). IgG and IgM apoB-IC and IgG and IgM anti-MDA-mimotope were measured at baseline and 3 months after treatment initiation.

Results

Patients had a mean age of 51 ± 15 years and 40% were male. Significant reductions in IgG apoB-IC levels were observed following treatment with high-intensity statins, add-on ezetimibe and add-on PCSK9i (by 18.3%, 17.5% and 25.5%, respectively, all p < 0.05). No significant changes in IgM apoB-IC, or IgG and IgM anti-MDA-mimotope levels were observed in any treatment group.

Conclusions

In individuals with Lp(a) levels ≥ 75 nmol/L, high-intensity statins, add-on ezetimibe and add-on PCSK9i reduced IgG apoB-IC but did not affect IgM apoB-IC, or IgG and IgM anti-MDA-mimotope levels. The clinical significance of these findings warrants further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lipoprotein(a)EzetimibeHydroxymethylglutaryl-CoA Reductase InhibitorsAutoantibodiesOxidative StressHumansMaleBiomarkersFemaleMiddle AgedImmunoglobulin MProspective StudiesApolipoprotein B-100Anticholesteremic AgentsImmunoglobulin GDrug Therapy, CombinationTreatment OutcomeAgedPCSK9 InhibitorsOxidation-Reduction

Stichwörter der Autor:innen

AutoantibodiesEzetimibeLipoprotein(a)Oxidative stressPCSK9 inhibitorsStatins

Substanzen

Lipoprotein(a)BiomarkersEzetimibeImmunoglobulin MHydroxymethylglutaryl-CoA Reductase InhibitorsAutoantibodiesApolipoprotein B-100Anticholesteremic AgentsImmunoglobulin GPCSK9 Inhibitors

Autor:innen und Institutionen

  • Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.
  • Department of Chemistry, Division of Organic Chemistry and Biochemistry, School of Natural Sciences, University of Ioannina, Ioannina, Greece.
  • Atherothrombosis Research Center, Laboratory of Biochemistry, Department of Chemistry, School of Natural Sciences, University of Ioannina, Ioannina, Greece.
  • Division of Cardiovascular Medicine, Sulpizio Cardiovascular Center, University of California San Diego, 9500 Gilman Dr, La Jolla, San Diego, CA, USA.
  • 1st Propedeutic Department of Medicine and Diabetes Center, School of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece. elibero@med.uoa.gr.

Förderung

  • Hellenic Atherosclerosis Society
  • University of Athens

Zitieren

APA

Koutsogianni, A. D., Barkas, F., Tellis, C., Tselepis, A., Liamis, G., Tsimikas, S., & Liberopoulos, E. (2026). Modulation of oxidation-related immune markers by lipid-lowering medications in individuals with elevated lipoprotein(a). Clinical Research in Cardiology, 115(8), 1400-1409. https://doi.org/10.1007/s00392-026-02896-5

Vancouver

Koutsogianni AD, Barkas F, Tellis C, Tselepis A, Liamis G, Tsimikas S, et al. Modulation of oxidation-related immune markers by lipid-lowering medications in individuals with elevated lipoprotein(a). Clinical Research in Cardiology. 2026;115(8):1400-1409. doi:10.1007/s00392-026-02896-5

BibTeX
@article{Koutsogianni2026,
  author = {Koutsogianni, Amalia Despoina and Barkas, Fotios and Tellis, Constantinos and Tselepis, Alexandros and Liamis, George and Tsimikas, Sotirios and Liberopoulos, Evangelos},
  title = {Modulation of oxidation-related immune markers by lipid-lowering medications in individuals with elevated lipoprotein(a)},
  journal = {Clinical Research in Cardiology},
  year = {2026},
  volume = {115},
  number = {8},
  pages = {1400--1409},
  doi = {10.1007/s00392-026-02896-5}
}
Kostenlos starten →